Liquidia will pursue final FDA approval for YUTREPIA™ (treprostinil) inhalation Liquidia will immediately request that District Court set aside injunction tied to '793 patent MORRISVILLE, N.C., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) (Liquidia or the Company) announced that the U.S. Court of Appeals for the Federal Circuit (Federal Circuit) today affirmed the earlier decision by the Patent Trial and Appeal Board (PTAB) which found all claims of U.S. Patent No. 10,716,793 ('793 P ...

财务数据和关键指标变化 - 公司在第三季度的收入为0.5百万美元,较去年同期有所增加,主要是由于有利的销售折扣和返利调整抵消了销售数量的下降 [6] - 销售成本略有下降至0.6百万美元,主要是由于与Sandoz的商业化协议延长导致无形资产摊销减少 [6] - 研发费用为7.4百万美元,较上年同期增加2.9百万美元,主要用于建立上市前商业供应、推进最近授权的L606临床项目以及支持人员增加 [6] - 管理费用为10.6百万美元,较上年同期增加3.9百万美元,主要由于与正在进行的诉讼相关的法律费用、为YUTREPIA潜在上市做准备的人员和商业费用以及股份支付费用增加 [6] - 公司在第三季度的净现金消耗为17.1百万美元,截至第三季度末现金余额为76.2百万美元 [6] 各条业务线数据和关键指标变化 - 公司的主要收入来自于treprostinil注射剂,该业务收入较去年同期有所增加 [6] - 公司正在开发的YUTREPIA和L606两个treprostinil吸入制剂项目进展顺利,YUTREPIA已在开放标签临床试验中显示出良好的耐受性和可滴定性,L606也在开放标签试验中显示出良好的安全性和有效性 [3][4] 各个市场数据和关键指标变化 - 公司认为PH-ILD市场的患者人群约为60,000人,这是一个巨大的未满足需求市场 [9][10] - 公司正在针对PAH和PH-ILD两个适应症积极准备YUTREPIA的商业化,并已建立了一支50人的销售团队,具有丰富的罕见病和肺动脉高压产品销售经验 [5][13] 公司战略和发展方向和行业竞争 - 公司认为YUTREPIA有望成为首选的prostacyclin治疗选择,其优势包括更好的耐受性、可滴定性和持久性 [17][18] - 公司正在与FDA讨论L606的注册路径,计划进行一项PH-ILD的III期临床试验,并利用开放标签试验的安全性数据支持PAH和PH-ILD的适应症 [13][14] - 公司正在应对United Therapeutics提起的专利诉讼,目前已获得PTAB裁定'793专利无效的有利决定,正在等待上诉结果 [3][4][19][25] 管理层对经营环境和未来前景的评论 - 公司对YUTREPIA和L606的临床和商业前景表示高度兴奋和乐观 [7][28] - 公司正做好充分准备,一旦获批将迅速进入市场,改变PAH治疗格局 [4][5] - 公司将继续保持谨慎的财务管理,同时把握法律和监管事件的发展机遇 [6]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39724 LIQUIDIA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 85-1710962 (Stat ...

Liquidia Corporation (NASDAQ:LQDA) Q2 2023 Earnings Conference Call August 10, 2023 8:30 AM ET Company Participants Jason Adair - Chief Business Officer Roger Jeffs - Chief Executive Officer Rusty Schundler - General Counsel Mike Kaseta - Chief Financial Officer Rajeev Saggar - Chief Medical Officer Conference Call Participants Mary Kate - Bank of America Julian Harrison - BTIG Serge Belanger - Needham Kambiz Yazdi - Jefferies Matthew Kaplan - Ladenburg Thalmann Operator Good morning, and welcome everyone t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39724 LIQUIDIA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 85-1710962 (State or ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39724 LIQUIDIA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 85-1710962 (State or ...

Liquidia Corporation (NASDAQ:LQDA) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Jason Adair - SVP, Corporate Development and Strategy Roger Jeffs - CEO Michael Kaseta - CFO Rajeev Saggar - CMO Scott Moomaw - Chief Commercial Officer Rusty Schundler - General Counsel Conference Call Participants Greg Harrison - Bank of America Serge Belanger - Needham Julian Harrison - BTIG Kambiz Yazdi - Jefferies Matt Kaplan - Ladenburg Operator Good morning, and welcome, everyone, to the Liq ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39724 LIQUIDIA CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 85-1710962 (State or Other Jurisdi ...

Liquidia Corporation (NASDAQ:LQDA) Q4 2022 Earnings Conference Call March 16, 2023 8:30 AM ET Company Participants Jason Adair - SVP, Corporate Development and Strategy Roger Jeffs - CEO Rajeev Saggar - CMO Rusty Schundler - General Counsel Mike Kaseta - CFO Conference Call Participants Gregory Harrison - Bank of America Kambiz Yazdi - Jefferies Serge Belanger - Needham Julian Harrison - BTIG Matt Kaplan - Ladenburg Thalmann Operator Good morning, and welcome, everyone, to the Liquidia Corporation's Full Ye ...

Liquidia Corporation (NASDAQ:LQDA) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET Company Participants Jason Adair – Senior Vice President-Corporate Development and Strategy Roger Jeffs – Chief Executive Officer Rusty Schundler – General Counsel Mike Kaseta – Chief Financial Officer Rajeev Saggar – Chief Medical Officer Conference Call Participants Greg Harrison – Bank of America Chris Howerton – Jefferies Julian Harris – BTIG Matt Kaplan – Ladenburg Serge Belanger – Needham & Company Operator ...